Sandoz

No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
Flag link:
FDA rejects Novartis’ Advair generic, leaving GSK without rival
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
FDA
Novartis
Advair
generics
GSK
Sandoz
Flag link:
Novartis aims for US approval of Humira biosimilar
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Novartis
Humira
biosimilars
AbbVie
Sandoz
Flag link:
Allergan says court affirms patent loss to Sandoz on eye drug
Allergan says court affirms patent loss to Sandoz on eye drug
Reuters
Allergan
patents
Sandoz
generics
Combigan
Flag link:
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbuster
Fierce Pharma
Novartis
Neulasta
biosimilars
Amgen
Sandoz
FDA
Flag link:
Novartis looks at offloading its generic pills business in U.S. as market continues to decline
Novartis looks at offloading its generic pills business in U.S. as market continues to decline
Fierce Pharma
Novartis
generics
Sandoz
M&A
Flag link:
Amazon in talks with generic drugmakers including Mylan, Sandoz about pharma play: report
Amazon in talks with generic drugmakers including Mylan, Sandoz about pharma play: report
Fierce Pharma
Amazon
generics
Sandoz
Mylan Labs
Flag link:
Sandoz head sees biosimilars as the light in the generics storm
Sandoz head sees biosimilars as the light in the generics storm
Fierce Pharma
generics
biosimilars
Sandoz
Peter Goldschmidt
Flag link:
Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars
Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars
Endpoints
Sandoz
Novartis
FDA
biosimilars
Flag link:
Novartis division closing Broomfield operations
Novartis division closing Broomfield operations
Broomfield Enterprise, Colorado
Novartis
drug manufacturing
Sandoz
generics
Flag link:
Lilly wards off another Alimta patent challenge, this time through IPR
Lilly wards off another Alimta patent challenge, this time through IPR
Fierce Pharma
Eli Lilly
Alimta
patents
IPR
lung cancer
Neptune
generics
Novartis
Sandoz
Flag link:
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Novartis stocks drug cabinet with "Big-3" arthritis blockbusters
Yahoo/Reuters
Novartis
rheumatoid arthritis
generics
Sandoz
Amgen
Enbrel
JNJ
Remicade
AbbVie
Humira
Flag link:
Biogen aims to block Tecfidera generics with flurry of lawsuits
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
Flag link:
Novartis scores second biosimilar approval in two weeks
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan
Flag link:
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Novartis
biosimilars
Rituxan
Roche
Sandoz
Flag link:
Novartis pushes further into pain with Durect deal
Novartis pushes further into pain with Durect deal
BioPharma Dive
Novartis
Durect
Sandoz
biosimilars
generics
Posimir
R&D
Flag link:
The Demise of the BPCIA Patent Dance?
The Demise of the BPCIA Patent Dance?
FDA Law Blog
BPCIA
patents
Genentech
Amgen
Sandoz
Avastin
Flag link:
In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift
In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift
Fierce Pharma
Amgen
Sandoz
Supreme Court
biosimilars
Flag link:
Amgen and the BPCIA Patent Dance – Redux
Amgen and the BPCIA Patent Dance – Redux
FDA Law Blog
Amgen
patents
BPCIA
FDA
Sandoz
Neupogen
generics
Genentech
Avastin
Flag link:
Amgen Fight Over Copies of Biotech Drugs Gets High Court Review
Amgen Fight Over Copies of Biotech Drugs Gets High Court Review
Bloomberg
Amgen
Supreme Court
Neupogen
Novartis
Sandoz
biosimilars
Flag link:

Pages